Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RS coming
Authorize the Board of Directors to amend the Company’s Fifth Amended and Restated Certificate of Incorporation to effect a reverse split of our issued and outstanding shares of common stock (the “Reverse Split”) upon a determination by the Board of Directors that such amendment is necessary and appropriate to maintain the continued listing of the common stock on The Nasdaq Capital Market, and such Reverse Split shall be at a ratio of between 1-for-10 and 1-for 20, inclusive, which ratio will be selected at the sole discretion of our Board of Directors at any whole number in the above range, with any fractional shares that would otherwise be issued as a result of the reverse split being rounded up to the nearest whole share;
I will have to do some more reading on the covenants??
Earliest I see a div coming back is first half 2017?
I do believe the div will be back for the long term growth of VNR
Don't see Vanguard getting out. They were caught like all other oil and gas businesses. Cash squeeze ?? I am long and profitable. Only gets better from here.
I agree this has no were to go but up.
Bottom is in for Oil and NG
When they start the dividend up again this will rise more
Once we see lots of news that oil and NG stablized then div will follow.
FluoroPharma Enters Development and Commercialization Agreement for China and Canada
MONTCLAIR, NJ -- (Marketwired) -- 06/06/16 -- FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agreement, Sinotau will develop and commercialize FluoroPharma's proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. These agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging.
In exchange, FluoroPharma expects to earn significant revenue based on unit sales to Sinotau and royalties based on Sinotau's sales of both imaging agents. In addition to a $550,000 upfront payment to FluoroPharma, up to $1.4 million in development milestone payments have also been established.
CardioPET, the company's lead imaging asset, is a fatty acid analog that targets the heart's primary energy source, and promises to provide unique insight into cardiac physiology versus older technologies like SPECT. CardioPET has completed enrollment in a Phase II study in Europe, and will advance to additional clinical studies in the US.
BFPET, entering Phase II studies in the US, is a marker of mitochondrial membrane integrity and can be used to evaluate myocardial perfusion with all the potential benefits of Fluorine-18 PET imaging, such as higher image resolution fewer image artifacts.
"We are pleased to have reached agreement with such a well-established partner as Sinotau," said Thomas Tulip, Ph.D., President and Chief Executive Officer of FluoroPharma. "As cardiovascular disease prevalence continues to rise in China, Canada, and around the world, we believe these assets will play a major role in how heart disease is diagnosed and managed appropriately."
According to the World Health Organization, the death rate from cardiovascular disease in China is nearly double that of cancer, and across Asia it now exceeds the mortality rates for CVD in other developed countries.
"We are pleased to have a partnership that combines FluoroPharma's radiopharmaceutical assets with our extensive development, regulatory, sales, and marketing capabilities," commented Xu Xinsheng, Sinotau President and CEO. "Our goal is to offer novel radiopharmaceutical approaches to improve care and patient outcomes with the growing cardiovascular disease problem in China. Ultimately, we are focused on having an impact on the growing concern of cost implications and quality of care in such a large population."
As part of the agreement, Sinotau is responsible for the costs and conduct of clinical studies and regulatory applications to obtain approval by the China Food and Drug Administration (CFDA) and Health Canada. Upon approval, Sinotau will be primarily responsible for all CardioPET and BFPET sales, marketing, market access and medical affairs activities in China and Canada. FluoroPharma and Sinotau will jointly support certain pre-market planning activities with a joint commitment on clinical and market development programs pending CFDA and Health Canada approvals.
"This is the first of many important partnerships which we anticipate during the course of our clinical development," added Dr. Tulip. "The ongoing advance of CVD and the need for better and more efficient solutions in healthcare worldwide give us increased confidence in the inherent value of our portfolio, and our ability to deliver shareholder value as well."
Watch what
Bankruptsy filing all ready said holders will be wiped out?
I really dont understand why the bankruptsy when they had 80% of note holders agree to reduced terms?
Only reason is to wipe out stock holders????
How can it have any value when going bankrupt??????????
Holdings are worthless after bankruptcy complete?
Comments please
Werte is the info on a RS ?
Or is it speculation?
Looks like something wakeing this stock up.
Any thoughts on why 3 weeks of inching up and no comments??
Old News in letter
Wonder why letter out?
Thanks, I missed that. I thought we had news first Qtr 2016.
Cheers
Expected news?
Any one know of any upcoming news?
Thought news on Fispemifine P2B due end first qtr 2016???????
Sure need good news
PMA application ?
Reviewing the news about the Co resubmitting a application I am trying to find out when a PMA application has actually been resubmitted. ???
Per company news releases
Nov 30 15 they meet with FDA and agreed on what needed to go fwd.
Dec 2, 15 agreement was reached on submitting PMA application.
I cant find any news on the actual re submittion of PMA ?????????????????
Any prof of a submission out there???????????????
Thanks
Phase 2B ?
The Co is due to post some info/results on fispemifene trial? first qtr 2016. Only 7 days left till end first qtr?
Thoughts. Could this run up be sign of good news???????????
Nice move last 3-4 days
? though news was due out end Q1 for syn 004?
Math check
Old share qty div by 25 = new shares
old price per share times 25 = new share price cost
To break even the market price has to rise 25 times.
R/S destroy holdings. Being this is the second R/S I dont see this ever breaking even long term.???
SYN-004 Phase 2B results end of Q1
Another report said March/April time frame
No firm date
SYN-010 Full data 2Q16
This Co needs SALES.
Signing up another distrubitor is nice but time for all those distributors to start selling.
Without sales we go no where.
The vol is up this am?
Nice but wondering whats helping it??
SYN (-22.6%) Ends MS drug study as data show no difference to placebo
Presentation
today announced that Richard Pascoe, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 9:30 a.m. Eastern Time. The conference will be held at The Waldorf Astoria, New York, NY. Mr. Pascoe will provide an update on Vitaros®, the Company's topical treatment for erectile dysfunction, as well as Apricus' drug candidates fispemifene, for the treatment of men with secondary hypogonadism and RayVa™, for the treatment of patients with Raynaud's phenomenon.
? any data due today?
Please advise what product you are talking about. Both of there P3 products not due till end of year???
Protocol
Has the company put out any news that the protocol has been finalized and study started? There 12/2 news end with them stating the protocol needed development.
That would be nice
Listening to TV doing interviews of fund mgr fro Dovos and he stated 93% cash only 7% in market
When they decide to buyback things will pop????
Great claw back with a bad Market
Stock purchase
Chief ex officer purchased 25,000 share on 1/14 and 1/15/16 at 47-49 cents
May be good news coming?
Synthetic Biologics recently finished a Phase II study of SYN-010 and plans to have a discussion with the FDA about the trials early in 2016. He said they have a second Phase II currently underway and plan to have that data for review by the middle of 2016. Will need to raise $$ to do phase 3.
No clue on why droped below $2. Expect its just bad market overall.??
Thanks
Any rumors on when Data or test results are do/release?
I dont see anything on FDA calender?
Thanks
Anyone have any news on yesterdays court action??????
To quiet??
MONTCLAIR, NJ -- (Marketwired) -- 12/29/15 -- FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today the appointment of Dr. Thomas Tulip, PhD as Chief Executive Officer.
Dr. Tulip joined FluoroPharma as President in October 2015 and assumed responsibility for the company's day-to-day operations, with a focus on global product and business development strategies.
Additionally, Walter Witoshkin has accepted the role of interim Chairman of the Board. Mr. Witoshkin has been a member of the Board since 2011. The company's previous Chairman and CEO, Thijs Spoor, will remain a member of the Board. The company also recently announced the resignation of Dr. Joseph A. Pierro from the Board, and the appointment to the Board of Austin Lewis IV, CEO of Lewis Asset Management Corporation.
Commenting on the announcement, Dr. Tulip stated, "I am extremely excited to work with the extended FluoroPharma team to advance the company to the crucial next step in its evolution. The company has accomplished many significant milestones under Thijs's leadership, for which we are extremely grateful. Thanks to his efforts, we believe we are now well positioned to move to the next phases of development for our promising cardiovascular imaging agent portfolio, and thereby demonstrate the value of our cutting edge technology."
Dr. Tulip added, "We will continue to focus on the execution of critical development milestones necessary to advance our assets to commercialization and to build shareholder value. We believe it is becoming increasingly clear that current challenges in the management of patients with cardiovascular disease will be better addressed with the innovative technologies that we are developing."
Dr. Tulip has spent more than 25 years in the development and commercialization of radiopharmaceuticals and imaging agents, with a track record of success in R&D, business development, brand and alliance management, and international business. From 2011-2015, he served in senior leadership roles at Navidea BioPharmaceuticals, Inc., where he led one of the few successful recent launches of an innovative radiopharmaceutical; established a number of global partnerships; and, in-licensed a pair of best-in-class neuroimaging assets. Previously, Dr. Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS), and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. While at BMS and DuPont, he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise; successfully built the BMS Medical Imaging international business; and led planning activities for innovative PET tracers at LMI/BMS. He was a Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies. Dr. Tulip was Chairperson of the Society of Nuclear Medicine Corporate Advisory Board and served as a Director of the Council on Radionuclides and Radiopharmaceuticals. He serves on the Board of Directors of the Medical Imaging Technology Association (MITA) and leads its PET Working Group. He earned a B.S. from the University of Vermont, and an M.S. and Ph.D. from the Northwestern University.
An investor call is planned for Wednesday, January 6th at which time Dr. Tulip will share his vision for FluoroPharma and address questions. Details of this call will be forthcoming shortly
BUMMER
12/23/15 shareholders approve three proposals, including a 1:15 reverse split of common shares effective January 7.
Shareholders also OK an increase in the number of authorized shares issuable after the reverse split and the issuance of common stock underlying convertible notes and warrants issued by the company pursuant to its November 4, 2015securities purchase agreement with five institutional investors. Under the terms of the deal, EnteroMedics will issue $23.5M in notes and warrants after the reverse split.
Net proceeds will fund commercialization activities for the vBloc neurometabolic therapy, clinical and product development, working capital and general corporate purposes.
No worry it jinked itself with 100-1 rs
Need a BIG eruption to go any were
Fid only shows 10% insider ownership
10% of 163,741,755 = 1,637,417.5
Agree
Any news of sales to any one will help.
Seems up against some powerful folks trying to sell there units. Last two major sales went to other companys??
Dont see were this will help GTHP
Diffrent company. I think it will actually hurt???????? GTHP sales?????
Another news story via BIOPHARMA 12/15/15
Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) shows upbeat performance increased 9.28% to end at $4.83. AstraZeneca reported that it was in talks that might lead to the takeover of privately held biotech firm Acerta Pharma, a possible $5B -plus contract deinked to build up its cancer drug portfolio.
AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction,” it stated in a brief statement. Credit Suisse analysts stated acalabrutinib’s considerable potential could also encourage other potential buyers. “If Acerta is open to a transaction, we would expect important interest from multiple other offerders,” they stated in a note. Force behind Aeterna Zentaris Inc. bullish run in this report?
Interesting List. Please advise were found. I have been working on such a list also but after reviewing diffrent data cant find all Dist? Also trying to match sales with Dist another hard project. With no sales via these dist something not quite lining up?????????
Conferance call
Anyone have info on conf call today to explain buyout?
Thanks